Posted by Michael Wonder on 24 Oct 2019
Women living with metastatic breast cancer in British Columbia now have public access to Kisqali
23 October 2019 - Novartis Pharmaceuticals Canada is pleased to announce that British Columbia will now reimburse Kisqali (ribociclib) for eligible patients in combination with an aromatase inhibitor (letrozole) under its provincial public drug program.
"The reimbursement of ribociclib (Kisqali) in British Columbia and certain other parts of Canada provides women living with advanced breast cancer with more treatment options that may potentially delay the progression of breast cancer and improve the duration and quality of their survival," said Dr. Karen Gelmon, Professor of Medicine, UBC and Medical Oncologist, BC Cancer.
